ZA201405108B - Substituted phenylazole derivative - Google Patents

Substituted phenylazole derivative

Info

Publication number
ZA201405108B
ZA201405108B ZA2014/05108A ZA201405108A ZA201405108B ZA 201405108 B ZA201405108 B ZA 201405108B ZA 2014/05108 A ZA2014/05108 A ZA 2014/05108A ZA 201405108 A ZA201405108 A ZA 201405108A ZA 201405108 B ZA201405108 B ZA 201405108B
Authority
ZA
South Africa
Prior art keywords
substituted
phenylazole derivative
derivative
substituted phenylazole
phenylazole
Prior art date
Application number
ZA2014/05108A
Other languages
English (en)
Inventor
Madoka Hoshino
Hidenori Namiki
Koji Matsumoto
Yuichi Ochiai
Shideo Yamanoi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of ZA201405108B publication Critical patent/ZA201405108B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ZA2014/05108A 2012-01-18 2014-07-11 Substituted phenylazole derivative ZA201405108B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012007840 2012-01-18
PCT/JP2013/050710 WO2013108800A1 (ja) 2012-01-18 2013-01-17 置換フェニルアゾール誘導体

Publications (1)

Publication Number Publication Date
ZA201405108B true ZA201405108B (en) 2015-10-28

Family

ID=48799224

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/05108A ZA201405108B (en) 2012-01-18 2014-07-11 Substituted phenylazole derivative

Country Status (21)

Country Link
US (3) US9233958B2 (enExample)
EP (2) EP3009433B1 (enExample)
JP (2) JP6104181B2 (enExample)
KR (1) KR20140113688A (enExample)
CN (1) CN104159892A (enExample)
AU (1) AU2013210394A1 (enExample)
BR (1) BR112014017656A2 (enExample)
CA (1) CA2861847A1 (enExample)
CO (1) CO7020920A2 (enExample)
ES (2) ES2640667T3 (enExample)
HK (2) HK1200824A1 (enExample)
IL (1) IL233682A0 (enExample)
IN (1) IN2014MN01442A (enExample)
MX (1) MX2014008790A (enExample)
NZ (1) NZ627303A (enExample)
PH (1) PH12014501646A1 (enExample)
RU (1) RU2014133738A (enExample)
SG (1) SG11201404026SA (enExample)
TW (1) TWI551590B (enExample)
WO (1) WO2013108800A1 (enExample)
ZA (1) ZA201405108B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN01442A (enExample) 2012-01-18 2015-07-03 Daiichi Sankyo Co Ltd
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (ja) * 2015-12-17 2017-06-22 第一三共株式会社 オキサジアゾール化合物の製造方法
EP3766879A1 (en) * 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
CN111388471B (zh) * 2020-03-03 2021-01-12 牡丹江医学院 一种治疗胆囊炎的药物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029974D0 (en) 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
JP4958560B2 (ja) 2003-12-24 2012-06-20 プロシディオン・リミテッド Gpcr受容体作動薬としてのヘテロ環誘導体
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
SI1931660T1 (sl) * 2005-09-29 2012-12-31 Sanofi Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila
NZ571869A (en) * 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists
GB0606913D0 (en) * 2006-04-06 2006-05-17 Prosidion Ltd Compounds
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
AU2008312948C1 (en) 2007-10-16 2012-08-09 Daiichi Sankyo Company, Limited Pyrimidyl indoline compound
EP2241558A1 (en) 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
WO2010119881A1 (ja) 2009-04-15 2010-10-21 第一三共株式会社 インドリン化合物
CN102574823B (zh) 2009-08-05 2014-09-10 第一三共株式会社 酰胺衍生物
JP5546543B2 (ja) * 2009-08-05 2014-07-09 第一三共株式会社 スルホン誘導体
JP5069813B2 (ja) * 2010-10-14 2012-11-07 第一三共株式会社 アシルベンゼン誘導体
PH12014500251A1 (en) 2011-07-29 2014-03-17 Daiichi Sankyo Co Ltd N-hetero-ring-substituted amide derivative
IN2014MN01442A (enExample) 2012-01-18 2015-07-03 Daiichi Sankyo Co Ltd

Also Published As

Publication number Publication date
EP2805941A1 (en) 2014-11-26
SG11201404026SA (en) 2014-11-27
US20140357675A1 (en) 2014-12-04
IN2014MN01442A (enExample) 2015-07-03
CN104159892A (zh) 2014-11-19
WO2013108800A1 (ja) 2013-07-25
ES2602962T3 (es) 2017-02-23
AU2013210394A1 (en) 2014-08-14
US20160081993A1 (en) 2016-03-24
JP2017052800A (ja) 2017-03-16
CA2861847A1 (en) 2013-07-25
JPWO2013108800A1 (ja) 2015-05-11
US9725438B2 (en) 2017-08-08
ES2640667T3 (es) 2017-11-03
TW201335141A (zh) 2013-09-01
BR112014017656A2 (pt) 2017-06-27
US9233958B2 (en) 2016-01-12
PH12014501646A1 (en) 2014-10-13
EP2805941B1 (en) 2016-08-17
EP2805941A4 (en) 2015-08-05
EP3009433A1 (en) 2016-04-20
TWI551590B (zh) 2016-10-01
US20160090375A1 (en) 2016-03-31
NZ627303A (en) 2015-11-27
IL233682A0 (en) 2014-09-30
AU2013210394A2 (en) 2014-10-16
HK1220448A1 (en) 2017-05-05
MX2014008790A (es) 2014-10-13
HK1200824A1 (en) 2015-08-14
CO7020920A2 (es) 2014-08-11
EP3009433B1 (en) 2017-06-21
KR20140113688A (ko) 2014-09-24
JP6104181B2 (ja) 2017-03-29
RU2014133738A (ru) 2016-03-10

Similar Documents

Publication Publication Date Title
ZA201407694B (en) Substituted pyrrolidine-2-carboxamides
ZA201409422B (en) Benzimidazole-proline derivatives
DK3327112T3 (en) Agse-deficient stamme
SG11201404344XA (en) Substituted pyrrolidine-2-carboxamides
ZA201408876B (en) Pyrrolotriazinone derivatives
IL236295A (en) The history of indanesulfamide
PL2838883T3 (pl) Nowe pochodne fenylo-tetrahydroizochinoliny
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
IL235925A0 (en) –o–3heteroaryl–inganol
ZA201405108B (en) Substituted phenylazole derivative
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
PT2873660T (pt) Derivado de indolecarboxamida
GB201207009D0 (en) Bi-pedal